|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0006826,
umls-concept:C0008059,
umls-concept:C0039194,
umls-concept:C0041700,
umls-concept:C0079748,
umls-concept:C0087111,
umls-concept:C0205179,
umls-concept:C0442711,
umls-concept:C1257890,
umls-concept:C1274040,
umls-concept:C1306673,
umls-concept:C2603343
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
1992-12-23
|
|
pubmed:abstractText |
Ninety-five unselected patients with stage III and IV T cell lymphoblastic lymphoma were treated according to the United Kingdom Children's Cancer Study Group protocol 8503. This was a continuous, intensive leukaemia type regimen including cranial irradiation (18 Gy in 10 fractions) and continuing chemotherapy for 2 years identical to the concurrent Medical Research Council ALL protocol. Four-year event-free survival was 65% (95% CI 50-80%) with no significant difference between stage III and stage IV cases. 4.2% of patients died of infection or non-tumour related events. Following relapse salvage was unlikely without high dose chemotherapy and bone marrow rescue. These results show an improvement over previous U.K. studies but we need to continue to search for subsets of patients with resistant disease for whom even more intensive therapy possibly combined with bone marrow rescue is required.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0007-1048
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
82
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
310-6
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:1419812-6-Mercaptopurine,
pubmed-meshheading:1419812-Adolescent,
pubmed-meshheading:1419812-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:1419812-Asparaginase,
pubmed-meshheading:1419812-Bone Marrow Transplantation,
pubmed-meshheading:1419812-Child,
pubmed-meshheading:1419812-Child, Preschool,
pubmed-meshheading:1419812-Combined Modality Therapy,
pubmed-meshheading:1419812-Daunorubicin,
pubmed-meshheading:1419812-Humans,
pubmed-meshheading:1419812-Infant,
pubmed-meshheading:1419812-Methotrexate,
pubmed-meshheading:1419812-Neoplasm Staging,
pubmed-meshheading:1419812-Precursor Cell Lymphoblastic Leukemia-Lymphoma,
pubmed-meshheading:1419812-Prednisolone,
pubmed-meshheading:1419812-Time Factors,
pubmed-meshheading:1419812-Trimethoprim-Sulfamethoxazole Combination,
pubmed-meshheading:1419812-Vincristine
|
|
pubmed:year |
1992
|
|
pubmed:articleTitle |
Treatment of advanced stage T cell lymphoblastic lymphoma: results of the United Kingdom Children's Cancer Study Group (UKCCSG) protocol 8503.
|
|
pubmed:affiliation |
Department of Paediatric Oncology, St Bartholomew's Hospital, London.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Multicenter Study
|
